Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study.
Aged
Bulgaria
/ epidemiology
Comorbidity
Cross-Sectional Studies
Depression
/ epidemiology
Europe, Eastern
/ epidemiology
Female
Forced Expiratory Volume
/ physiology
Humans
Hungary
/ epidemiology
Male
Middle Aged
Physical Endurance
/ physiology
Prevalence
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Respiratory Function Tests
/ methods
Severity of Illness Index
Symptom Assessment
/ methods
Walk Test
/ methods
CAT
COPD
Comorbidities
GOLD classification
mMRC
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
14
01
2019
revised:
15
03
2019
accepted:
17
03
2019
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
2
5
2020
Statut:
ppublish
Résumé
The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT >10 is not equivalent to mMRC >2 for assessing symptom burden. ClinicalTrials.gov, identifier NCT02119494.
Sections du résumé
BACKGROUND
The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants.
METHODS
The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy.
RESULTS
The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups.
CONCLUSIONS
The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT >10 is not equivalent to mMRC >2 for assessing symptom burden.
TRIAL REGISTRATION
ClinicalTrials.gov, identifier NCT02119494.
Identifiants
pubmed: 30961941
pii: S0954-6111(19)30082-4
doi: 10.1016/j.rmed.2019.03.007
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02119494']
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-148Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.